Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Utilization of New Visualization Software for Deep Brain Stimulation Programming Using a Multiple-Source, Constant-Rechargeable System
Movement Disorders
Movement Disorders Posters (7:00 AM-5:00 PM)
106
We describe utilization of newly available visualization software for use as a Deep Brain Stimulation (DBS) planning tool during initial programming of patients with Parkinson’s disease (PD) as part of an ongoing device registry. 

Optimization of DBS programming consists of a trial-and-error process involving appraisal of various stimulation parameters in which both clinician assessment and patient reporting of clinical benefit are required. However, this can be an inefficient and lengthy undertaking. The use of a visualization tool that illustrates location of the DBS lead in the patient’s own-segmented anatomy may help improve efficiency of achieving programming optimization and outcomes specific to the individual patient. 
This is a sub-study of ongoing prospective, multicenter, registry (NCT02071134) in which novel DBS visualization software (GUIDE XT, Boston Scientific) is utilized during initial device programming of patients implanted with a multiple-source, constant-current DBS System (Vercise, Boston Scientific).  The software uses pre-op MRI and post-op CT to create patient-specific anatomy enabling visualization based-programming and identification of the lead relative to anatomical targets.  The time duration to reach effective stimulation settings at the conclusion of initial programming (e.g.  monopolar review) using this visualization tool is collected and assessed. All participating patients must hold anti-parkinsonian medications overnight per standard of care (meds OFF). 
To date, 5 patients have been assessed in this ongoing sub-study. Settings suggested by the novel visualization software provided a starting point for initial programming post-DBS implant.  Initial programming sessions (post-implant), where the visualization software was utilized to provide initial settings, lasted a mean 20.8 ± 4.7 minutes.  
Preliminary results suggest shorter initial programming sessions are possible using a visualization software tool compared to traditional trial-and-error approach as reported in the published literature. Shorter and more efficient programming sessions may lead to reduced programming visit time and improve resource utilization.
Authors/Disclosures
Jason L. Aldred, MD, FÂ鶹´«Ã½Ó³»­ (Selkirk Neurology)
PRESENTER 		Dr. Aldred has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boston Scientific. Dr. Aldred has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbvie. Dr. Aldred has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Allergan . Dr. Aldred has received personal compensation in the range of $0-$499 for serving as a Consultant for Quadralynx. Dr. Aldred has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Aldred has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Boston Scientific. Dr. Aldred has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medtronic. Dr. Aldred has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Abbvie. Dr. Aldred has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Acorda. Dr. Aldred has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Allergan. Dr. Aldred has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Boston Scientific. Dr. Aldred has received personal compensation in the range of $100,000-$499,999 for serving on a Speakers Bureau for TEVA. Dr. Aldred has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Medtronic. Dr. Aldred has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for US World Meds. Dr. Aldred has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Kyowa Kirin. Dr. Aldred has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sunovion. Dr. Aldred has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amneal. Dr. Aldred has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Dr. Aldred has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Neurocrine. Dr. Aldred has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merz. Dr. Aldred has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Boston Scientific. Dr. Aldred has received personal compensation in the range of $50,000-$99,999 for serving as an Expert Witness for Arete Neuroscience, PLLC. The institution of Dr. Aldred has received research support from Biogen . The institution of Dr. Aldred has received research support from Abbvie. The institution of Dr. Aldred has received research support from Merz. The institution of Dr. Aldred has received research support from AstraZeneca. The institution of Dr. Aldred has received research support from Neurocrine. The institution of Dr. Aldred has received research support from Aptinyx. The institution of Dr. Aldred has received research support from Cerevance. The institution of Dr. Aldred has received research support from Boston Scientific . The institution of Dr. Aldred has received research support from Parkinson Foundation . The institution of Dr. Aldred has received research support from Roche. The institution of Dr. Aldred has received research support from Sage Therapeutics. The institution of Dr. Aldred has received research support from Annovis. The institution of Dr. Aldred has received research support from Biovie. The institution of Dr. Aldred has received research support from NeuroDerm. The institution of Dr. Aldred has received research support from PhotoPharma. The institution of Dr. Aldred has received research support from Lilly. Dr. Aldred has received research support from Capsida Biotherapeutics. Dr. Aldred has received research support from Teva. Dr. Aldred has received research support from Lundbeck. Dr. Aldred has received research support from Denali Therapeutics. Dr. Aldred has received research support from Intra-Cellular Therapies Inc.. Dr. Aldred has received research support from Vima Therapeutics. Dr. Aldred has received research support from Ventus Therapeutics. Dr. Aldred has received research support from Scion NeuroStim .
Theresa A. Zesiewicz, MD (University of South Florida) Dr. Zesiewicz has received personal compensation for serving as an employee of Medscape. Dr. Zesiewicz has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lexeo. Dr. Zesiewicz has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Steminent. Dr. Zesiewicz has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Larimar. Dr. Zesiewicz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Zesiewicz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Zesiewicz has received intellectual property interests from a discovery or technology relating to health care. Dr. Zesiewicz has received intellectual property interests from a discovery or technology relating to health care. Dr. Zesiewicz has received intellectual property interests from a discovery or technology relating to health care.
Yarema Bezchlibnyk Yarema Bezchlibnyk has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Medtronic. Yarema Bezchlibnyk has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for PMT Inc. Yarema Bezchlibnyk has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Abbott. Yarema Bezchlibnyk has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Boston Scientific. Yarema Bezchlibnyk has received research support from Medtronic.
Jonathan Carlson No disclosure on file
Lilly Chen (Boston Scientific) Lilly Chen has received personal compensation for serving as an employee of Boston Scientific .
Roshini Jain Roshini Jain has received personal compensation for serving as an employee of Boston Scientific. Roshini Jain has received stock or an ownership interest from Boston Scientific.